[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351050-105":59,"doc-detail-351050-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-lipid-nanoparticles-delivering-genetic-medicines-for-solid-cancers-review","Advances in lipid nanoparticles delivering genetic medicines for solid cancers - Review","","Nucleic acid lipid nanoparticle (LNP) technology enables delivery of genetic medicines to solid tumors, addressing barriers created by the tumor microenvironment (TME). Solid cancers require solutions that overcome complex local architecture and allow both direct effects on cancer cells and indirect modulation of tumor immunity. The review covers recent progress, including targeted and local/systemic delivery strategies, genetic payload mechanisms, challenges, and future prospects for oncology therapeutics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-lipid-nanoparticles-delivering-genetic-medicines-for-solid-cancers-review/351050/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-lipid-nanoparticles-delivering-genetic-medicines-for-solid-cancers-review/351050.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are solid tumors challenging for nucleic acid delivery with nanoparticles?","Question",{"text":112,"@type":113},"Solid tumors have a complex tumor microenvironment (TME) that can act as a barrier to nanoparticle delivery, complicating effective genetic medicine uptake.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can LNP-delivered genetic medicines exert anti-cancer effects directly?",{"text":117,"@type":113},"They can directly alter cancer cells by suppressing oncogenic drivers and pathways with small noncoding RNAs, or by overexpressing toxin genes or tumor suppressors.",{"name":119,"@type":110,"acceptedAnswer":120},"How can LNP delivery produce indirect anti-tumor effects?",{"text":121,"@type":113},"It can modify the immune state of the tumor environment via immunomodulatory cytokine delivery, activatable receptor overexpression to stimulate immune cells, or antigen-binding scaffolds to direct immunity toward cancer cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351050,1790557404,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nAdvances in lipid nanoparticles  \ndelivering genetic medicines for solid cancers  \nFan Yang1,2 and Tristan A. Scott 1,2  \n1Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, 1500 E. Duarte Rd., Duarte, CA 91010, USA;  \n2Center for Gene Therapy, City of Hope, 1500 E. Duarte Rd., Duarte, CA 91010, USA  \nNucleic acid lipid nanoparticle (LNP) technology has enabled the delivery of genetic medicines to solid tumors, opening new avenues for oncology therapeutics. Solid tumors present unique challenges to nucleic acid delivery because of their complex tumor microenvironment (TME), which acts as a barrier to NP delivery. Nevertheless, nucleic acid LNPs carry diverse genetic medicine modalities that can exert anti-cancer effects. The versatility of LNPs allows both local and systemic administrations for the delivery of gene therapy payloads to solid cancer, with the additional capability to selectively target specific cell types through conjugation of targeting ligands onto the LNPs. Genetic medicines delivered by LNPs can directly affect cancer cells, such as by suppressing oncogenic drivers and cancer pathways with small noncoding RNAs, or through overexpression of toxin genes or tumor suppressors. Non-cancer components of the tumor, such as tumor-associated vasculature, can also be targeted and disrupted to inhibit the structures that support tumor growth. Alternatively, LNP delivery of genetic medicines can indirectly elicit anti-tumor effects by modifying the immune state of the tumor environment through delivery of immunomodulatory cytokines, overexpression of activatable receptors to stimulate immune cells with agonists, or antigen-binding scaffolds to direct immunity towards a cancer cell. In this review, we summarize recent advances, challenges, and prospects of LNP delivery of genetic medicines to treat solid tumors.  \nINTRODUCTION  \nThe success of coronavirus disease 2019 (COVID-19) mRNA vaccine supercharged the development and applications of lipid nanoparticles (LNPs) for the delivery of genetic medicines. The prior success of LNP-mediated delivery of small regulatory RNAs to treat liver-associated hereditary transthyretin amyloidosis (hATTR), later approved by the Food and Drug Administration (FDA) asthe drug Onpattro, demonstrated its utility in disease-modifying activity with low toxicity. 1–3 LNP-based vaccines for cancer long proceeded the momentum generated by the rapid deployment and widespread success of the COVID-19 vaccine, which further highlighted that transient, non-viral LNPs represent a robust delivery system that could be coupled with genetic medicines as nextgeneration solid cancer interventions.  \nCancer is a complex ecosystem of cancerous and non-cancerous cells with a complex array of cellular interactions dictating disease outcomes. Broadly cancer is categorized into solid and hematological malignancies and is the result of a concert of genetic mutations and structural genomic changes induced by various stresses that form neoplastic lesions (smoking, alcohol, UV exposure, carcinogens, chronic inflammation) . The accumulation of these genomic changes with oncogenic potential is then combined with cellular interactions that facilitate uncontrolled tumor growth. Solid cancers emerge as a mass of cells within a specific tissue or organ and present unique treatment challenges. For example, chimeric antigen receptor (CAR) technology, in which immune cells (traditionally cytotoxic T cells) are modified to artificially express an anti-cancer ligand attached to a signaling domain, is highly effective at inducing curative states in certain hematological malignancies.3 However, although significant advances have been made, the application of CAR therapy against solid cancers has faced significant delays and challenges, largely as a result of the complex and hostile tumor microenvironment (TME) .4  \nThe TME is a multifaceted ecosystem, with","cbCaig6bKMf8xJ2h","https://ap.wps.com/l/cbCaig6bKMf8xJ2h","pdf",3155421,21,"English","# Introduction\n## LNP delivery enabled by COVID-19 mRNA success\n## Solid cancer ecosystem and tumor microenvironment barriers\n## Components of TME and implications for therapy","[{\"question\":\"Why are solid tumors challenging for nucleic acid delivery with nanoparticles?\",\"answer\":\"Solid tumors have a complex tumor microenvironment (TME) that can act as a barrier to nanoparticle delivery, complicating effective genetic medicine uptake.\"},{\"question\":\"How can LNP-delivered genetic medicines exert anti-cancer effects directly?\",\"answer\":\"They can directly alter cancer cells by suppressing oncogenic drivers and pathways with small noncoding RNAs, or by overexpressing toxin genes or tumor suppressors.\"},{\"question\":\"How can LNP delivery produce indirect anti-tumor effects?\",\"answer\":\"It can modify the immune state of the tumor environment via immunomodulatory cytokine delivery, activatable receptor overexpression to stimulate immune cells, or antigen-binding scaffolds to direct immunity toward cancer cells.\"}]","Advances in lipid nanoparticles delivering genetic medicines for solid cancers - Review | PDF",1790092403,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bf948e6a931a541c88a4387781d1c54.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f0b072f96b2c90848a582ca7df3d706.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e09e97866045f3df22fb1734f5c9a0b.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe5f1e5ce7cc0a8694bd3a98201d5c94.webp",980,754]